drugset / Trial / NCT02675491
Phase 1 Study of DS-6051b in Japanese Subjects With Advanced Solid Malignant Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase 1 study to evaluate the safety, tolerability, and pharmacokinetics of DS-6051b in Japanese subjects with advanced solid malignant tumors harboring either a ROS1 or NTRK fusion gene.
Timeline
- Start
- 2016-02-10
- Primary completion
- 2021-12-27
- Completion
- 2021-12-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DS-6051b | Unknown | 400 mg | — |
| Subject | DS-6051b | Unknown | 800 mg | — |